澳大利亚倡导者力促医疗保健计划覆盖罕见性免疫紊乱的SCIG治疗。 Australian advocates push for Medicare to cover SCIg therapy for rare immune disorders.

倡导者敦促澳大利亚政府为罕见的免疫紊乱患者的次皮免疫球蛋白(SCIg)治疗提供资金,以其有效性和生活质量利益为例。 Advocates are urging the Australian government to fund subcutaneous immunoglobulin (SCIg) therapy for patients with rare immune disorders, citing its effectiveness and quality-of-life benefits. 这种治疗已经私人提供,但没有完全由《医疗保健计划》提供,给病人带来了财政负担。 The treatment, already available privately, is not fully covered by Medicare, placing a financial burden on patients. 团体表示,扩大供资将改善获得保健服务的机会并降低长期保健费用。 Groups say expanded funding would improve access and reduce long-term healthcare costs.